# EDGAR Filing Document

**Accession Number:** 0001242825
**File Stem:** 0000875320-25-000234
**Filing Date:** 2025-11
**Character Count:** 7464
**Document Hash:** 5e11aac93380907ab09cf4004a9d9a49
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000875320-25-000234.hdr.sgml**: 20251117

**ACCESSION NUMBER**: 0000875320-25-000234

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251113

**FILED AS OF DATE**: 20251117

**DATE AS OF CHANGE**: 20251117

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LEIDEN JEFFREY M
- **CENTRAL INDEX KEY:** 0001242825

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19319
- **FILM NUMBER:** 251491208

**MAIL ADDRESS:**
- **STREET 1:** 127 SOUTH BEACH RD
- **CITY:** HOBE SOUND
- **STATE:** FL
- **ZIP:** 33455
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VERTEX PHARMACEUTICALS INC / MA
- **CENTRAL INDEX KEY:** 0000875320
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043039129
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 6173416393

**MAIL ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LEIDEN JEFFREY M<br><sub>(Last) (First) (Middle)</sub><br>C/O VERTEX PHARMACEUTICALS INCORPORATED<br>50 NORTHERN AVENUE<br><sub>(Street)</sub><br>BOSTON, MA 02210<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Executive Chairman_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>VERTEX PHARMACEUTICALS INC / MA [ VRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-13 |  | M |  | 19688 | A | $91.05 | 43714 | D |  |
| Common Stock | 2025-11-13 |  | S<sup>(1)</sup> |  | 18528 | D | 440.22<sup>(2)(3)</sup> | 25186 | D |  |
| Common Stock | 2025-11-13 |  | S<sup>(1)</sup> |  | 1160 | D | 441.05<sup>(2)(4)</sup> | 24026 | D |  |
| Common Stock | 2025-11-14 |  | M |  | 13835 | A | $91.05 | 37861 | D |  |
| Common Stock | 2025-11-14 |  | M |  | 39769 | A | $86.52 | 77630 | D |  |
| Common Stock | 2025-11-14 |  | S<sup>(1)</sup> |  | 32234 | D | 440.30<sup>(2)(5)</sup> | 45396 | D |  |
| Common Stock | 2025-11-14 |  | S<sup>(1)</sup> |  | 21330 | D | 441.35<sup>(2)(6)</sup> | 24066 | D |  |
| Common Stock | 2025-11-14 |  | S<sup>(1)</sup> |  | 40 | D | $442 | 24026 | D |  |
| Common Stock |  |  |  |  |  |  |  | 440 | I | 401(k) |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $91.05 | 2025-11-13 |  | M |  |  | 19688 | <sup>(7)</sup> | 2026-02-01 | Common Stock | 19688 | $0 | 13836 | D |  |
| Stock Option (Right to Buy) | $91.05 | 2025-11-14 |  | M |  |  | 13835 | <sup>(7)</sup> | 2026-02-01 | Common Stock | 13835 | $0 | 1 | D |  |
| Stock Option (Right to Buy) | $86.52 | 2025-11-14 |  | M |  |  | 39769 | <sup>(7)</sup> | 2027-02-02 | Common Stock | 39769 | $0 | 63781 | D |  |

---

### Footnotes:

(1) Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

(2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(3) Open market sales reported on this line occurred at a weighted average price of $440.22 (range $440.00 to $440.99).

(4) Open market sales reported on this line occurred at a weighted average price of $441.05 (range $441.00 to $441.10).

(5) Open market sales reported on this line occurred at a weighted average price of $440.30 (range $440.00 to $440.99).

(6) Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99).

(7) Fully vested.

**Signature:** /s/ Christiana Stevenson, Attorney-in-Fact  
**Date:** 2025-11-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**